Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: CDK4

Summary for CDK4

Gene information	Gene symbol	CDK4
	Ensembl ID	ENSG00000135446
	Entrez ID	1019
	Gene name	cyclin dependent kinase 4
	Synonyms	PSK-J3
	Gene type	protein_coding
	UniProtAcc	P11802

Top

Dataset with differentially expressed gene: CDK4

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.959469	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.383233	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.345312	1.16e-24
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.863119	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.721279	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.960263	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.26135	2.92e-31
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.6076	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.533058	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.554128	4.90e-44
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.553752	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.472402	6.67e-36
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.370181	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Erythrocytes	-0.419425	7.73e-03
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.552816	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.606576	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.635202	0.00e+00

Top

Expression of CDK4 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CDK4

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
CDK4	Aberration of the Drug's Therapeutic Target
CDK4	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating CDK4

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CDK4	hsa-miR-7152-5p	97.2843	NM_000075
CDK4	hsa-miR-486-5p	92.2823	NM_000075
CDK4	hsa-miR-6832-5p	92.2497	NM_000075
CDK4	hsa-miR-4280	91.0011	NM_000075
CDK4	hsa-miR-6844	90.648	NM_000075
CDK4	hsa-miR-568	86.474	NM_000075
CDK4	hsa-miR-4756-3p	85.9775	NM_000075
CDK4	hsa-miR-5196-5p	85.2947	NM_000075
CDK4	hsa-miR-4747-5p	85.2947	NM_000075
CDK4	hsa-miR-4668-3p	84.6975	NM_000075
CDK4	hsa-miR-3714	81.9049	NM_000075

Page: 1

Top

Motifs and transcription factors (TFs) regulating CDK4

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CDK4	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
CDK4	transfac_pro__M05628	ZNF735 (directAnnotation).
CDK4	hocomoco__KLF13_HUMAN.H11MO.0.D	KLF13 (directAnnotation).
CDK4	taipale_tf_pairs__GCM1_ETV1_RTRNNGGCGGAAGTN_CAP	ETV1; GCM1 (directAnnotation).
CDK4	metacluster_195.2	EGR2; KLF10; KLF10; KLF11; KLF11; KLF11; KLF13; KLF13; KLF13; KLF13; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF15; KLF15; KLF16; KLF3; KLF8; KLF9; KLF9; KLF9; SP1; SP1; SP1; SP3; SP3; SP4; SP8; SP8; SP8; SP9; SP9 (directAnnotation). EGR1; KLF1; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF2; KLF3; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF9; SP1; SP3; SP4; SP4; SP5; SP5; SP5; SP6; SP7; SP8; SP9 (inferredBy_Orthology).
CDK4	metacluster_3.14	WT1; WT1 (directAnnotation).
CDK4	transfac_pro__M06827	ZBTB11 (directAnnotation).
CDK4	jaspar__MA1493.1	HES6 (directAnnotation).
CDK4	transfac_pro__M05670	ZNF37A (directAnnotation).
CDK4	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
CDK4	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
CDK4	transfac_pro__M01182	HINFP (directAnnotation).
CDK4	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
CDK4	metacluster_85.6	ZNF74 (directAnnotation).
CDK4	transfac_pro__M06919	ZNF652 (directAnnotation).
CDK4	metacluster_10.32	MYC (directAnnotation).
CDK4	transfac_pro__M03581	TBP (directAnnotation).
CDK4	dbtfbs__ZFP91_K562_ENCSR898XMH_merged_N1	ZFP91 (directAnnotation).
CDK4	hocomoco__OTX1_HUMAN.H11MO.0.D	OTX1 (directAnnotation).
CDK4	metacluster_44.6	NKX2-5 (directAnnotation).
CDK4	transfac_public__M00220	SREBF1 (directAnnotation).
CDK4	jaspar__MA1563.2	SOX18 (directAnnotation).
CDK4	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
CDK4	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
CDK4	taipale__ELK1_full_NACTTCCGSCGGAARMN_repr	ELK1 (directAnnotation).
CDK4	homer__NCCACGTG_c-Myc	MYC (directAnnotation).
CDK4	metacluster_57.3	ARNT; ATF3; ATF3; ATF3; ATF3; BHLHE40; BHLHE40; BHLHE40; BHLHE41; BHLHE41; BHLHE41; MITF; MITF; MITF; MLX; MLXIPL; SREBF1; SREBF1; SREBF1; SREBF1; SREBF2; SREBF2; SREBF2; TFE3; TFEC; USF1; USF1; USF1; USF1; USF1; USF1; USF1; USF1; USF1; USF2; USF2; USF2; USF2; USF2; USF2; USF2; USF2; USF2; USF2; USF2; USF2; USF2; ZNF507 (directAnnotation). ARNTL; BHLHE40; BHLHE40; BHLHE41; HELT; HES1; HES2; HES3; HES5; HES6; HES7; HEY1; HEY2; HEYL; MLX; MLX; SREBF1; SREBF2; TFE3; USF1; USF1; USF2; USF2 (inferredBy_Orthology).
CDK4	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
CDK4	taipale_tf_pairs__ETV5_EVX1_RSCGGWAATKR_CAP	ETV5; EVX1 (directAnnotation).
CDK4	kznf__ZNF441_Imbeault2017_OM_RCADE	ZNF441 (directAnnotation).

Page: 1

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
CDK4	"Abemaciclib"	DB12001	small molecule
CDK4	"Alvocidib"	DB03496	small molecule
CDK4	"Fostamatinib"	DB12010	small molecule
CDK4	"Palbociclib"	DB09073	small molecule
CDK4	"Purvalanol"	DB02733	small molecule
CDK4	"Ribociclib"	DB11730	small molecule
CDK4	"Trilaciclib"	DB15442	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."

1	Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells
2	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
3	A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study
4	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesPigment Cell Melanoma
5	Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer